Form 4: Crinetics Pharmaceuticals' Chief Scientific Officer Sells Shares

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock on August 12, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On August 12, 2024, Stephen F. Betz, the Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of the company's common stock.
• The sale was executed automatically under a pre-existing Rule 10b5-1 trading plan.
• The shares were sold in open market transactions at a volume-weighted average price of $47.68 per share.
• Following the transaction, Betz directly owns 72,611 shares of Crinetics Pharmaceuticals.
• The price range for the sales on August 12, 2024, was between $47.60 and $47.80 per share.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to an insider stock sale. It doesn't inherently convey positive or negative sentiment about the company's prospects, as the sale was pre-planned.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It provides transparency into the transactions of company executives and their holdings in the company. Investors often monitor these filings to gain insights into management's perspective on the company's stock.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates